Enjoy complimentary customisation on priority with our Enterprise License!
***1. Executive Summary
***2. Market Landscape
**2.1 Market ecosystem
*Exhibit 01: Parent market
**2.2: Market Characteristics
**2.3 Value chain analysis
*Exhibit 02: Value chain analysis- Pharmaceuticals
*2.3.1 R&D and drug discovery
*2.3.2 Integration and product development
*2.3.3 Manufacturing
*2.3.4 Outbound logistics
*2.3.5 Marketing and sales
*2.3.6 Support services
*2.3.7 Innovation
***3. Market Sizing
**3.1 Market definition
*Exhibit 03: Offerings of vendors included in the market definition
**3.2 Market segment analysis
*Exhibit 04: Market segments
**3.3 Market size 2020
**3.4 Market outlook: Forecast for 2020 - 2025
*Exhibit 05: Global - Market size and forecast 2019 - 2024 ($ million)
*Exhibit 06: Global- Market size and forecast 2019-2024 ($ million), exclusive of COVID-19 impact
*Exhibit 07: Global market: Year-over-year growth 2019 - 2024 (%)
***4. Five Forces Analysis
**4.1 Five Forces Summary
*Exhibit 08: Five forces analysis 2020 & 2025
**4.2 Bargaining power of buyers
**4.3 Bargaining power of suppliers
**4.4 Threat of new entrants
**4.5 Threat of substitutes
**4.6 Threat of rivalry
**4.7 Market condition
*Exhibit 09: Market condition - Five forces 2019
***5. Market Segmentation by Product
**5.1 Market segments
*The segments covered in this chapter are:
*Exhibit 10: Product - Market share 2019-2024 (%)
**5.2 Comparison by Product
*Exhibit 11: Comparison by Product
**5.3 Ischemic and neuro-ischemic ulcer therapeutics - Market size and forecast 2019-2024
*Exhibit 12: Ischemic and neuro-ischemic ulcer therapeutics - Market size and forecast 2019-2024 ($ million)
*Exhibit 13: Ischemic and neuro-ischemic ulcer therapeutics - Market size and forecast 2019-2024 ($million), exclusive of COVID-19 impact
*Exhibit 14: Ischemic and neuro-ischemic ulcer therapeutics - Year-over-year growth 2019-2024 (%)
**5.4 Neuropathic ulcer therapeutics - Market size and forecast 2019-2024
*Exhibit 15: Neuropathic ulcer therapeutics - Market size and forecast 2019-2024 ($ million)
*Exhibit 16: Neuropathic ulcer therapeutics - Market size and forecast 2019-2024 ($million), exclusive of COVID-19 impact
*Exhibit 17: Neuropathic ulcer therapeutics - Year-over-year growth 2019-2024 (%)
**5.5 Market opportunity by Product
*Exhibit 18: Market opportunity by Product
***6. Customer landscape
**6.1 Customer landscape
*Exhibit 19: Customer landscape
***7. Geographic Landscape
**7.1 Geographic segmentation
*Exhibit 20: Market share by geography 2019-2024 (%)
**7.2 Geographic comparison
*Exhibit 21: Geographic comparison
**7.3 North America - Market size and forecast 2019-2024
*Exhibit 22: North America - Market size and forecast 2019-2024 ($ million)
*Exhibit 23: North America - Market size and forecast 2019-2024 ($million), exclusive of COVID-19 impact
*Exhibit 24: North America - Year-over-year growth 2019-2024 (%)
**7.4 Europe - Market size and forecast 2019-2024
*Europe - Market size and forecast 2019-2024 ($ million)
*Exhibit 25: Europe - Market size and forecast 2019-2024 ($million), exclusive of COVID-19 impact
*Exhibit 26: Europe - Year-over-year growth 2019-2024 (%)
**7.5 Asia - Market size and forecast 2019-2024
*Exhibit 27: Asia - Market size and forecast 2019-2024 ($ million)
*Exhibit 28: Asia - Market size and forecast 2019-2024 ($million), exclusive of COVID-19 impact
*Exhibit 29: Asia - Year-over-year growth 2019-2024 (%)
**7.6 ROW - Market size and forecast 2019-2024
*Exhibit 30: ROW - Market size and forecast 2019-2024 ($ million)
*Exhibit 31: ROW - Market size and forecast 2019-2024 ($million), exclusive of COVID-19 impact
*Exhibit 32: ROW - Year-over-year growth 2019-2024 (%)
**7.7 Key leading countries
*Exhibit 33: Key leading countries
**7.8 Market opportunity by geography
*Exhibit 34: Market opportunity by geography ($ million)
***8. Drivers, Challenges, and Trends
**8.1 Market drivers
*8.1.1 Strong drug development pipeline
*8.1.2 Increasing incidence of diabetic foot ulcers
*8.1.3 Rising number of diabetes awareness programs
**8.2 Market challenges
*8.2.1 Impact of complex pathogenesis in clinical trial design
*8.2.2 High entry barriers
*8.2.3 Poor wound care management
**8.3 Market trends
*8.3.1 Increasing wound healing therapeutics
*8.3.2 Increased outsourcing of non-core activities
*8.3.3 Increase in R&D activities
***9. Vendor Landscape
**9.1 Competitive scenario
**9.2 Vendor landscape
*Exhibit 35: Vendor Landscape
**9.3 Landscape disruption
*Exhibit 36: Landscape disruption
**9.4 Industry risks
*Exhibit 37: Industry risks
***10. Vendor Analysis
**10.1 Vendors covered
*Exhibit 38: Vendors covered
**10.2 Market positioning of vendors
*Exhibit 39: Market positioning of vendors
*10.3 3M Co.
*Exhibit 40: 3M Co. - Overview
*Exhibit 41: 3M Co. - Business segments
*Exhibit 42: 3M Co. - Key news
*Exhibit 43: 3M Co. - Key offerings
*Exhibit 44: 3M Co. - Segment focus
**10.4 Baxter International Inc.
*Exhibit 45: Baxter International Inc. - Overview
*Exhibit 46: Baxter International Inc. - Business segments
*Exhibit 47: Baxter International Inc. - Key news
*Exhibit 48: Baxter International Inc. - Key offerings
*Exhibit 49: Baxter International Inc. - Segment focus
**10.5 ConvaTec Inc.
*Exhibit 50: ConvaTec Inc. - Overview
*Exhibit 51: ConvaTec Inc. - Product and service
*Exhibit 52: ConvaTec Inc. - Key offerings
*10.6 Dr. Reddys Laboratories Ltd.
*Exhibit 53: Dr. Reddys Laboratories Ltd. - Overview
*Exhibit 54: Dr. Reddys Laboratories Ltd. - Business segments
*Exhibit 55: Dr. Reddys Laboratories Ltd. - Key news
*Exhibit 56: Dr. Reddys Laboratories Ltd. - Key offerings
*Exhibit 57: Dr. Reddys Laboratories Ltd. - Segment focus
**10.7 Fresenius SE & Co. KGaA
*Exhibit 58: Fresenius SE & Co. KGaA - Overview
*Exhibit 59: Fresenius SE & Co. KGaA - Business segments
*Exhibit 60: Fresenius SE & Co. KGaA - Key news
*Exhibit 61: Fresenius SE & Co. KGaA - Key offerings
*Exhibit 62: Fresenius SE & Co. KGaA - Segment focus
**10.8 GlaxoSmithKline Plc
*Exhibit 63: GlaxoSmithKline Plc - Overview
*Exhibit 64: GlaxoSmithKline Plc - Business segments
*Exhibit 65: GlaxoSmithKline Plc - Key news
*Exhibit 66: GlaxoSmithKline Plc - Key offerings
*Exhibit 67: GlaxoSmithKline Plc - Segment focus
**10.9 Merck & Co. Inc.
*Exhibit 68: Merck & Co. Inc. - Overview
*Exhibit 69: Merck & Co. Inc. - Business segments
*Exhibit 70: Merck & Co. Inc. - Key news
*Exhibit 71: Merck & Co. Inc. - Key offerings
*Exhibit 72: Merck & Co. Inc. - Segment focus
**10.10 Mylan NV
*Exhibit 73: Mylan NV - Overview
*Exhibit 74: Mylan NV - Business segments
*Exhibit 75: Mylan NV - Key news
*Exhibit 76: Mylan NV - Key offerings
*Exhibit 77: Mylan NV - Segment focus
**10.11 Pfizer Inc.
*Exhibit 78: Pfizer Inc. - Overview
*Exhibit 79: Pfizer Inc. - Business segments
*Exhibit 80: Pfizer Inc. - Key news
*Exhibit 81: Pfizer Inc. - Key offerings
*Exhibit 82: Pfizer Inc. - Segment focus
**10.12 Smith & Nephew Plc
*Exhibit 83: Smith & Nephew Plc - Overview
*Exhibit 84: Smith & Nephew Plc - Business segments
*Exhibit 85: Smith & Nephew Plc - Key news
*Exhibit 86: Smith & Nephew Plc - Key offerings
*Exhibit 87: Smith & Nephew Plc - Segment focus
***11. Appendix
**11.1 Scope of the report
*11.1.1 ????Market definition
*11.1.2 ????Objectives
*11.1.3 ????Notes and caveats
**11.2 Currency conversion rates for US$
*Exhibit 88: ?Currency conversion rates for US$?
**11.3 Research Methodology
*Exhibit 89: ?Research Methodology
*Exhibit 90: ??Validation techniques employed for market sizing?
*Exhibit 91: ??Information sources
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.